Literature DB >> 26847042

PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.

Sungmin Woo1, Sang Youn Kim1, Joongyub Lee2, Seung Hyup Kim1,3, Jeong Yeon Cho4,5.   

Abstract

OBJECTIVES: To evaluate PI-RADSv2 for predicting pathological downgrading after radical prostatectomy (RP) in patients with biopsy-proven Gleason score (GS) 7(3+4) PC.
METHODS: A total of 105 patients with biopsy-proven GS 7(3+4) PC who underwent multiparametric prostate MRI followed by RP were included. Two radiologists assigned PI-RADSv2 scores for each patient. Preoperative clinicopathological variables and PI-RADSv2 scores were compared between patients with and without downgrading after RP using the Wilcoxon rank sum test or Fisher's exact test. Logistic regression analyses with Firth's bias correction were performed to assess their association with downgrading.
RESULTS: Pathological downgrading was identified in ten (9.5 %) patients. Prostate-specific antigen (PSA), PSA density, percentage of cores with GS 7(3+4), and greatest percentage of core length (GPCL) with GS 7(3+4) were significantly lower in patients with downgrading (p = 0.002-0.037). There was no significant difference in age and clinical stage (p = 0.537-0.755). PI-RADSv2 scores were significantly lower in patients with downgrading (3.8 versus 4.4, p = 0.012). At univariate logistic regression analysis, PSA, PSA density, and PI-RADSv2 scores were significant predictors of downgrading (p = 0.003-0.022). Multivariate analysis revealed only PSA density and PI-RADSv2 scores as independent predictors of downgrading (p = 0.014-0.042).
CONCLUSIONS: The PI-RADSv2 scoring system was an independent predictor of pathological downgrading after RP in patients with biopsy-proven GS 7(3+4) PC. KEY POINTS: • PI-RADSv2 was an independent predictor of downgrading in biopsy-proven GS 7(3+4) PC • PSA density was also an independent predictor of downgrading • MRI may assist in identifying AS candidates in biopsy-proven GS 7(3+4) PC patients.

Entities:  

Keywords:  Downgrade; Gleason score; MRI; PI-RADS; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26847042     DOI: 10.1007/s00330-016-4230-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system.

Authors:  C C Pan; S R Potter; A W Partin; J I Epstein
Journal:  Am J Surg Pathol       Date:  2000-04       Impact factor: 6.394

2.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

3.  Standardizing the power of the Hosmer-Lemeshow goodness of fit test in large data sets.

Authors:  Prabasaj Paul; Michael L Pennell; Stanley Lemeshow
Journal:  Stat Med       Date:  2012-07-26       Impact factor: 2.373

4.  Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Hedvig Hricak; Evis Sala; Junting Zheng; Chaya S Moskowitz; Melanie Bernstein; James A Eastham; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2014-08-07       Impact factor: 5.315

5.  A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Authors:  Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

6.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

Authors:  Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2015-06-18       Impact factor: 11.105

Review 8.  Imaging prostate cancer: a multidisciplinary perspective.

Authors:  Hedvig Hricak; Peter L Choyke; Steven C Eberhardt; Steven A Leibel; Peter T Scardino
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

Review 9.  PI-RADS version 2: what you need to know.

Authors:  T Barrett; B Turkbey; P L Choyke
Journal:  Clin Radiol       Date:  2015-07-29       Impact factor: 2.350

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  12 in total

1.  Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.

Authors:  Sonia Gaur; Stephanie Harmon; Lauren Rosenblum; Matthew D Greer; Sherif Mehralivand; Mehmet Coskun; Maria J Merino; Bradford J Wood; Joanna H Shih; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2018-05-07       Impact factor: 3.959

Review 2.  PI-RADS v2: Current standing and future outlook.

Authors:  Clayton P Smith; Barış Türkbey
Journal:  Turk J Urol       Date:  2018-05-01

3.  Multiparametric MR imaging of peripheral zone prostate cancer: effect of postbiopsy hemorrhage on cancer detection according to Gleason score and tumour volume.

Authors:  Sung Il Jung; Hae Jeong Jeon; Hee Sun Park; Mi Hye Yu; Young Jun Kim; Seung Eun Lee; So Dug Lim
Journal:  Br J Radiol       Date:  2018-03-09       Impact factor: 3.039

4.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

5.  Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.

Authors:  Sonia Gaur; Stephanie Harmon; Sherif Mehralivand; Sandra Bednarova; Brian P Calio; Dordaneh Sugano; Abhinav Sidana; Maria J Merino; Peter A Pinto; Bradford J Wood; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2018-03-31       Impact factor: 4.813

6.  PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.

Authors:  Sung Yoon Park; Su-Jin Shin; Dae Chul Jung; Nam Hoon Cho; Young Deuk Choi; Koon Ho Rha; Sung Joon Hong; Young Taik Oh
Journal:  Eur Radiol       Date:  2016-12-12       Impact factor: 5.315

Review 7.  Active surveillance for intermediate-risk prostate cancer.

Authors:  Madhur Nayan; Filipe L F Carvalho; Adam S Feldman
Journal:  World J Urol       Date:  2022-01-19       Impact factor: 4.226

8.  Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.

Authors:  Xiang-Ke Niu; Jun Li; Susant Kumar Das; Yan Xiong; Chao-Bing Yang; Tao Peng
Journal:  BMC Med Imaging       Date:  2017-02-01       Impact factor: 1.930

Review 9.  Prostate Imaging-Reporting and Data System Version 2: Beyond Prostate Cancer Detection.

Authors:  Sung Yoon Park; Nam Hoon Cho; Dae Chul Jung; Young Taik Oh
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

10.  Optimising preoperative risk stratification tools for prostate cancer using mpMRI.

Authors:  Lars A R Reisæter; Jurgen J Fütterer; Are Losnegård; Yngve Nygård; Jan Monssen; Karsten Gravdal; Ole J Halvorsen; Lars A Akslen; Martin Biermann; Svein Haukaas; Jarle Rørvik; Christian Beisland
Journal:  Eur Radiol       Date:  2017-10-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.